Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUC1 Vaccine in Patients With Newly Diagnosed Advanced Adenomas
NCT02134925Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2014
- Primary completion
- Jan 2017
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of MUC1 peptide-poly-ICLC vaccine in Colorectal Adenoma (CRA), sponsored by National Cancer Institute. Started Jun 2014; status: active, not recruiting.
02
Drugs
MUC1 peptide-poly-ICLC vaccine
03
Conditions
Colorectal Adenoma (CRA)
Beyond the preview
Go deeper on NCT02134925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02134925.